Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of “Moderate Buy” from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.89.

A number of brokerages recently weighed in on ATEC. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Friday. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Piper Sandler restated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research note on Friday. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd.

Alphatec Stock Performance

Shares of ATEC stock opened at $12.00 on Friday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm has a 50-day moving average of $10.46 and a 200-day moving average of $9.86. Alphatec has a one year low of $4.88 and a one year high of $13.79. The company has a market cap of $1.75 billion, a P/E ratio of -9.38 and a beta of 1.20.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Alphatec’s quarterly revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.34) EPS. Equities research analysts forecast that Alphatec will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the sale, the chief executive officer now directly owns 5,857,603 shares in the company, valued at $62,324,895.92. This represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total transaction of $365,317.56. Following the transaction, the executive vice president now owns 668,977 shares of the company’s stock, valued at $7,245,020.91. This trade represents a 4.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 222,113 shares of company stock valued at $2,519,725. Corporate insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

Large investors have recently modified their holdings of the business. Congress Asset Management Co. increased its stake in Alphatec by 235.4% in the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock valued at $3,993,000 after acquiring an additional 305,296 shares during the last quarter. Barclays PLC grew its holdings in shares of Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after purchasing an additional 133,653 shares during the last quarter. Rhumbline Advisers boosted its position in Alphatec by 1.3% during the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company’s stock valued at $1,277,000 after buying an additional 1,746 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Alphatec by 20.0% during the fourth quarter. Russell Investments Group Ltd. now owns 199,886 shares of the medical technology company’s stock valued at $1,835,000 after buying an additional 33,362 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the period. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.